Adjuvant treatment recommendations for patients with ER-positive/HER2-negative early breast cancer by Swiss tumor boards using the 21-gene recurrence score (SAKK 26/10)

Table 5 Distribution of second tumor board recommendations according to the recurrence score

Risk category	Low-risk group (N = 154)		Non-low-risk group (N = 67)		Total
Risk category	CT + HT	HT	CT + HT	HT	Total
All recommendations	28	126	32	35	221
RS 0–17 (low)	4	96	6	28	134 (61%)
RS 18–30 (intermediate)	18	30	12	7	67 (30%)
RS 31–100 (high)	6	0	14	0	20 (9%)

ISSN: 1471-2407